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ABSTRACT
Introduction Idiopathic pulmonary fibrosis (IPF) is 
a fibrotic disease of unknown aetiology with a poor 
prognosis. Several clinical trials of nintedanib in patients 
with IPF have reported its inhibitory effect on reduced 
lung function, incidence of acute exacerbation of IPF 
and worsened health- related quality of life. Although 
nintedanib has a manageable safety and tolerability profile 
over long- term use, it was discontinued in over 20% of 
patients because of adverse events such as diarrhoea 
and liver dysfunction. This might explain why nintedanib 
use in patients with IPF is not widespread, especially 
among patients with early- stage IPF. In the present study, 
we aimed to clarify the efficacy, safety and tolerability 
of nintedanib in patients with stage I/II IPF, based on 
the Japanese IPF disease severity staging classification 
system.
Methods and analysis This is an ongoing, prospective, 
multicentre observational cohort study of patients with 
stage I/II IPF who will start receiving nintedanib. Totally, 
215 patients at 35 sites in Kyushu and Okinawa, Japan 
will be enrolled and followed up for 3 years. Nintedanib 
therapy would be initiated at the discretion of the 
investigator. The primary endpoint, change in forced vital 
capacity (FVC) at 156 weeks, will be shown as the mean 
change in FVC from baseline to week 156 with 95% CIs 
estimated using the Wald method. The safety endpoint—
occurrence of adverse events—will be assessed in each 
system organ class/preferred term.
Ethics and dissemination The study protocol and 
informed consent documents were approved by the 
Institutional Review Board at Nagasaki University Hospital 
(approval number 19102146) and each participating 
site. Written informed consent was obtained from all 
participants. Patient recruitment has begun. The results 
will be disseminated through scientific peer- reviewed 
publications and national and international conferences.
Trial registration number UMIN000038192.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a 
fibrotic disease of an unknown aetiology 
affecting the lung interstitium. Its primary 
pathogenesis is suspected to be chronic injury 
to the alveolar epithelial cells, which causes 
chronic fibrosis. IPF occurs in 50%–60% of 
patients with idiopathic interstitial pneu-
monia. It has a poor prognosis with a median 
survival time of approximately 3 years.1 2 A 
decline in pulmonary function, worsening 
of pulmonary symptoms and physical activity, 
and acute exacerbation have been identi-
fied as risk factors for the poor prognosis.3 
Following a definitive diagnosis, the median 
survival time of patients with percentage vital 
capacity (%VC) of >80% in pulmonary func-
tion test, in a relatively early stage, has been 
reported to be 62 months. Furthermore, the 
median survival of patients with stage I and 
II IPF, classified by the Japanese IPF disease 
severity staging classification system, is 62 and 
51 months, respectively.4 These results indi-
cate that even patients in the early stages do 
not have a good prognosis.
Treatments that modulate inflammation 
(eg, steroids and immunosuppressants) 
have failed or had deleterious effects in 
patients with IPF; currently, two medica-
tions, nintedanib and pirfenidone, have 
been shown to be safe and effective in the 
treatment of IPF.5 6 Several clinical trials of 
nintedanib in patients with IPF have reported 
Strengths and limitations of this study
 ► This is a real- world, prospective, multicentre obser-
vational cohort study.
 ► The results will reveal the efficacy, safety and toler-
ability of nintedanib in Japanese patients with early- 
stage idiopathic pulmonary fibrosis.
 ► The study is designed as a prospective, single- arm, 
non- randomised study.
 ► Participating sites are located in specific areas of 
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its inhibitory effect on reduced lung function, incidence 
of acute exacerbation of IPF and worsened health- related 
quality of life (QOL).5–7 Pooled data from phase II and III 
trials have revealed that nintedanib reduced all- cause and 
on- treatment mortality.8 In addition, INPULSIS- ON, an 
open- label nintedanib extension trial, revealed the effect 
of nintedanib in reducing the annual rate of decline in 
forced vital capacity (FVC) and showed that acute exac-
erbation of IPF persists beyond 4 years.7 A reduction 
in the annual rate of FVC decline was also observed in 
patients with early- stage IPF.7 These results suggest that 
early treatment with nintedanib maintains QOL and 
prolongs survival, which could influence the perspective 
of patients with IPF. Therefore, the use of nintedanib is 
recommended for patients with IPF in the official Amer-
ican Thoracic Society/European Respiratory Society/
Japanese Respiratory Society/Latin American Thoracic 
Association (ATS/ERS/JRS/ALAT) clinical practice 
guidelines3 and Japanese guidelines for the treatment of 
IPF.9
However, adverse events, such as diarrhoea, nausea 
and liver dysfunction, have been attributed to nintedanib 
use. Although nintedanib has a manageable safety and 
tolerability profile for long- term use, it was discontinued 
in over 20% of patients because of adverse events.6 7 
The long- term continuation rate has been reported to 
be significantly higher in the mild- to- moderate patient 
group.10 The effect of nintedanib on slowing disease 
progression is also sustained over a long term, and 
long- term treatment with nintedanib has an acceptable 
safety and tolerability profile in Asian patients with IPF.11 
Furthermore, a subgroup analysis of the INPULSIS trials 
showed comparable efficacy and safety of nintedanib in 
Japanese patients and the overall population.12 However, 
no prospective study has reported the efficacy, safety and 
tolerability of nintedanib in Japanese patients with early- 
stage IPF.
The present study aimed to clarify the (1) efficacy, 
safety and tolerability of nintedanib over a 1- year obser-
vation period, and (2) efficacy of nintedanib over a 3- year 
observation period in patients with stage I/II IPF based 
on the Japanese IPF disease severity staging classification 




This is an ongoing, prospective, multicentre observa-
tional cohort study. The present study has been designed 
in accordance with the Strengthening the Reporting 
of Observational Studies in Epidemiology Statement 
guidelines.
Patient and public involvement
Patients will not be involved in the study.
Participant selection and screening
Study population
In total, 215 participants diagnosed with IPF will be 
recruited from sites in Kyushu and Okinawa, Japan, 
from 24 October 2019. IPF will be diagnosed by pulmo-
nary physicians in each site according to the ATS/ERS/
JRS/ALAT guidelines.13 Usual interstitial pneumonia or 
probable usual interstitial pneumonia pattern in high- 
resolution CT (HRCT) will be diagnosed as IPF if surgical 
lung biopsy is not performed. The choice of treatment 
will be based on regular medical practice and at the 
discretion of the physician. The specific inclusion and 
exclusion criteria for the trial are provided below.
Inclusion criteria
1. Diagnosis of IPF according to the ATS/ERS/JRS/
ALAT guidelines.13
2. Stage I or II IPF based on the Japanese IPF disease se-
verity classification.4
Stage I: PaO2 at rest ≥80 mm Hg.
Stage II: PaO2 at rest 70–80 mm Hg, and SpO2 ≥90% 
during a 6- min walk test.
3. Patients who will start nintedanib for IPF.
4. Patients who are able and willing to provide written in-
formed consent.
Exclusion criteria
1. Patients who have initiated therapy with any antifibrot-
ic agent for IPF.
2. Patients treated with corticosteroids (more than a 
prednisolone equivalent dose, 10 mg/day) or immu-
nosuppressive agents.
3. Patients who are participating in any other interven-
tional clinical trials.
4. Patients who are undergoing malignant tumour treat-
ment.
5. Patients with a contraindication for nintedanib 
treatment.
Data collection and management
Patients will be included in the study following the provi-
sion of informed signed consent and if all inclusion 
criteria are fulfilled without meeting any of the exclusion 
criteria. The following data will be collected and regis-
tered during a month before starting nintedanib: sex, 
date of birth, height, weight, body surface area, smoking 
history, social history (presence or absence of dust expo-
sure, contact with birds and occupational history), family 
history of interstitial pneumonia, date of IPF diagnosis, 
presence or absence of surgical lung biopsy, findings of 
bronchoalveolar lavage fluid, history of treatment for 
interstitial pneumonia, previous and current concom-
itant medications, respiratory function tests in the past 
6–15 months, medical history and complications. The 
following physical examination results will be collected: 
SpO2, dyspnoea scale score (modified Medical Research 
Council), biological assessments (including blood count 
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lung disease markers (Krebs von den Lungen-6 (KL-6), 
Surfactant Protein- D (SP- D)).14 HRCT, pulmonary func-
tion tests, blood gas analysis and the 6- minute walk test 
will be performed within 3 months before inclusion in 
the study, and the Japanese classification of IPF disease 
severity and the Gender–Age–Physiology Index for IPF15 
will be determined. Electrocardiography and echocardi-
ography results will be collected if they are performed 
within the past 6 months.
Study treatment will be started within a month after the 
provision of informed signed consent, and the starting 
date and daily dose of nintedanib will be recorded. 
Follow- up data will be collected at weeks 4, 12, 24, 36, 
52, 78, 104, 130 and 156. During each visit, a physical 
examination including SpO2 and biological assessments 
will be regularly performed. The occurrence of adverse 
and acute exacerbation events16 will be recorded at clin-
ical visits and between visits as required to monitor treat-
ment safety. The daily dose of nintedanib and the date 
of any reduction or discontinuation of nintedanib will be 
recorded. The reduction or discontinuation of nintedanib 
will be determined in each site. In addition, the results of 
serum interstitial lung disease markers, pulmonary func-
tion test, HRCT, 6- min walk test and blood gas analysis will 
be collected at each interval (table 1). The patients will 
be followed up until death, lung transplantation, diag-
nosis of non- IPF or study completion. Efficacy and safety 
endpoints will be collected up to 52 weeks after the start of 
oral administration (safety priority observation period), 
and an interim analysis will be conducted 52 weeks after 
the initiation of oral administration. To observe the long- 
term therapeutic effect, details will be collected during 
the 156 weeks after the start of oral administration 
(effectiveness- focused observation period). Patients will 
be registered using a interactive web response system and 
source data entry will be made in a standard case report 
form, with direct electronic entry using REDCap hosted 
by the Nagasaki University Hospital.
Primary endpoint
Change in FVC at 156 weeks.
Safety endpoints
Occurrence of adverse events in each system organ class/
preferred term (SOC/PT; MedDRA V.22.1).
Secondary endpoints
1. Time to the incidence of adverse events leading to nin-
tedanib treatment discontinuation.
2. Time to the incidence of adverse events leading to nin-
tedanib dose reduction.
3. Incidence of adverse events leading to nintedanib 
treatment discontinuation.
4. Incidence of adverse events leading to nintedanib dose 
reduction.
Further endpoints
1. Time to the first acute exacerbation of IPF.
2. Time to absolute 10% decline in %FVC from baseline.
Table 1 Schedule of activities
Time Screening
1- year observation period 3- year observation period Stop 
NIN
Stop 
study4W 12W 24W 36W 52W 78W 104W 130W 156W
Consent ● ― ― ― ― ― ― ― ― ― ― ―
Severity ● ― ― ― ― ― ― ― ― ― ― ―
NIN (dose) ― ● ● ● ● ● ● ● ● ● 〇 〇
Symptom (mMRC) ● ― ― ● ― ● ● ● ● ● 〇 〇
SpO2                     
Routine blood tests ● ● ● ● ● ● ● ● ● ● 〇 〇
Serum ILD markers ● ― ― ● ― ● ● ● ● ● 〇 〇
Blood gas analysis ● ― ― ― ― ● ― ● ― ● 〇 〇
Chest XP, HRCT ● ― ― ― ― ● ― ● ― ● 〇 〇
6MWT ● ― ― ― ― ● ― ● ― ● 〇 〇
PFT ● ― ― ● ― ● ● ● ● ● 〇 〇
ECG, UCG 〇 ― ― ― ― 〇 ― 〇 ― 〇 〇 〇
Events ― ● ● ● ● ● ● ● ● ● 〇 〇
Acute exacerbation ― ● ● ● ● ● ● ● ● ● 〇 〇
Drugs other than NIN ― ● ● ● ● ● ● ● ● ● 〇 〇
Prognosis ― ― ― ― ― ― ― ― ― ● ― ●
Adverse events ― ● ● ● ● ● ● ● ● ● 〇 〇
●: Mandatory; 〇: if possible.
HRCT, high- resolution CT; ILD, interstitial lung disease; mMRC, modified Medical Research Council dyspnoea scale; 6MWT, 6 min walk test; NIN, 
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3. Time to death.
4. Change in FVC from baseline at each interval.
5. Change in the diffusion capacity of carbon monoxide 
(DLco) from baseline at each interval.
6. Change in serum biomarkers (KL-6 and SP- D) from 
baseline at each interval.
7. Judgement of therapeutic efficacy at 52, 104 and 156 
weeks (a change in absolute FVC of 10% or a change 




The sample size was determined from a precision analysis 
of the primary endpoint and aimed to assure that liver 
injury was observed in at least one patient. The precision 
analysis was conducted based on the mean change in FVC 
from baseline to week 192 in 138 patients obtained from 
the nintedanib- continuing group of a previous study.7 
Using this result, we set the sample size of 44 to a 95% CI 
(CI.95) narrower than 15 (mL) obtained with the prob-
ability exceeding 95%. Finally, we estimated the propor-
tion of dropout patients as 24/119 based on the results of 
the Asian cohort in a previous study11 and set the sample 
size as 215.
The sample size needed to observe liver injury was deter-
mined as follows. (1) The CI.95 of the frequency of liver 
injury in a patient was estimated using the Wilson score 
interval. The point estimate of the frequency was obtained 
from the Japanese package insert of Ofev (17 events in 
638 patients). We obtained the lower and upper limits 
of the CI.95 (lower and upper control limits) as 0.0156 
and 0.0451, respectively. (2) The number of patients who 
exhibited liver injury was simulated from the binomial 
distribution with sample sizes of 150, 180, 190, 195, 200, 
205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 300 and 
310. The lower control limit was adopted as parameter p 
of the binomial distribution because the purpose of this 
sample size assessment was to ensure the observation of 
the clinical course of liver injury occurring as an adverse 
effect of nintedanib, even if the true frequency of liver 
injury occurrence is extremely small within the possible 
range. For each sample size, 5000 observations were 
generated. (3) The probability 1−pN (0) was obtained for 
each sample size N, where pN (k) denotes the probability 
mass function of the number of patients who exhibited 
liver injury k of the N patients, which was estimated from 
the empirical distribution of the 5000 observations. (4) 
Finally, the sample size for this study was determined as 
n=inf {N: 1−pN (0)>0.95}. We obtained n=215.
Enrollment will continue until at least 50% of patients 
with stage I IPF according to the Japanese classification of 
disease severity are recruited.
Analysis of outcome measures
Details of the analysis methods will be documented in 
the statistical analysis plan that will be signed off before 
database freeze with all participants’ data. The primary 
analysis will focus on the mean change in FVC from base-
line to week 156 with the CI.95 estimated using the Wald 
method. For the safety analysis, adverse events in each 
SOC/PT will be assessed. Regarding the secondary anal-
ysis, the Kaplan- Meier method will be used to estimate the 
survival function of time to events. A Cox proportional 
hazard model will be used for conducting an exploratory 
analysis with patient characteristics. The association of 
clinical factors with the occurrence of adverse events 
leading to treatment discontinuation or dose reduction 
of nintedanib will be analysed using logistic regression 
models. The data collected in a time- series manner will 
be analysed using mixed- effect models.
DISCUSSION
To the best of our knowledge, this is the first prospec-
tive, multicentre observational cohort study to clarify the 
efficacy, safety and tolerability of nintedanib in Japanese 
patients with early- stage IPF classified according to the 
Japanese IPF disease severity staging classification system.
Several clinical trials of nintedanib in patients with 
IPF have reported its inhibitory effect on reduced lung 
function, incidence of acute exacerbation of IPF and 
worsened health- related QOL.5–7 Based on these trials, 
the use of nintedanib is recommended for the treatment 
of patients with IPF in the official ATS/ERS/JRS/ALAT 
clinical practice guidelines3 and Japanese IPF treatment 
guidelines.9 However, drug therapy in patients with IPF 
is not widespread.18 Data from Europe and the USA 
suggest that only approximately 60% of patients with 
IPF are receiving nintedanib or pirfenidone. Almost a 
quarter of the pulmonologists were more concerned 
about the adverse effects of drug therapy than the risk 
of disease progression, whereas patients have reported 
that they wanted more information about the prognosis 
of their disease and pharmacological treatment options. 
Furthermore, the patients were more concerned about 
preventing disease progression than avoiding medication- 
related adverse effects.19 20 A similar survey was conducted 
in Japan, and comparable results were reported; 40% of 
patients with IPF received nintedanib or pirfenidone, 
and only 15% and 34% of patients with IPF stage I and 
II received these drugs, respectively. Physicians tend 
to focus more on symptoms and adverse effects during 
communication with patients.21 22 Antifibrotic therapies 
are associated with several adverse events, including 
gastrointestinal events. The most common adverse effect 
of nintedanib is diarrhoea, which was reported in 62.4% 
of patients treated with nintedanib compared with 18.4% 
of patients who were administered a placebo in the 
INPULSIS trials.23 Although most of the adverse effects of 
nintedanib are controllable, the risk–benefit balance of 
nintedanib treatment for patients in the early stage of IPF 
should be clarified in a real- world setting.
In the present study, we plan to observe patients for 
3 years and examine the FVC change, and incidence of 
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and dose reduction of nintedanib. Time to acute exacer-
bation, death, FVC, DLco decline and changes in serum 
biomarkers will also be examined. The present study will 
clarify the efficacy, safety and tolerability of nintedanib 
for patients with early- stage IPF in the real world. As a 
result, the risk–benefit balance of nintedanib treatment 
could be clarified for patients with early stages of IPF.
ETHICS AND DISSEMINATION
This study will be performed in accordance with the 
Declaration of Helsinki and Ethical Guidelines for 
Medical and Health Research Involving Human Subjects. 
The study protocol and informed consent documents 
were approved by the Institutional Review Board at Naga-
saki University Hospital (approval number 19102146) 
and each participating site. Written informed consent 
was obtained from all participants. Patient recruitment 
has begun and is ongoing. The results will be dissemi-
nated through scientific peer- reviewed publications and 
national and international conferences.
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